Name:
YONDELIS (development of innovative drugs through marine organisms)

Developed by:
PHARMAMAR, SPAIN

Country(ies) involved:
Spain

Funding sources:
National

General idea:
APLIDIN is an anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans.

Description:
APLIDIN specifically binds to the eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programed death). Plitidepsin is approved Australia for the treatment of multiple myeloma, and it has received orphan drug designation in the European Union and the United States of America.
Clinical studies with Lurbinectedin in clinicaltrials.gov and in clinicaltrialsregister.eu

TRL:
9. Actual system proven in operational environment

IPR involved:
Yes

Sources:
Literarute review. Link: https://pharmamar.com/science-and-innovation/oncology-pipeline/?lang=en